Temporal and dose-dependent relationships between in vivo B cell receptor-targeted proliferation and deletion-induced by a microbial B cell toxin.
The effective functioning of the adaptive immune system requires careful clonal regulation within the B cell compartment. Some microbial pathogens produce virulence factors, like staphylococcal protein A, which interact at high frequencies with B lymphocyte through unconventional binding sites in BCR variable region frameworks conserved during evolution. We have characterized the in vivo effect of staphylococcal protein A treatment on peripheral B cells bearing susceptible BCR, and found a dose-dependent direct relationship over the range of 2 mg to <0.2 microg in the magnitude of induced BCR-targeted supraclonal cell death. Significantly, some level of targeted B cell proliferation was always detectable, with greatest interim supraclonal expansion demonstrated at 2 days after 20-microg treatment. Subsequently, this transient expansion always collapsed. In direct comparisons, i.p. treatment was more efficacious than i.v. treatment, although at higher doses this finding was less marked. These studies elucidate a general paradigm in which in vivo encounters with a B cell superantigen are uniformly associated with proliferative expansion followed by deletion that is more rapid and complete with higher doses, whereas lower doses lead to greater transient in vivo expansion with delayed deletion to levels at later times that are still quantitatively proportional to the dose. Our results document the potent in vivo B cell-targeted properties of a microbial B cell superantigen, even at submicrogram doses associated with great molar excess of circulating Ig, and clearly illustrate the intertwined relationships between targeted proliferative cycling and apoptotic death that is induced by a microbial B cell superantigen.
Goodyear
Carl S
CS
Department of Medicine, Rheumatic Diseases Core Center, University of California, San Diego, La Jolla, 92093, USA.
Sugiyama
Fujimi
F
Silverman
Gregg J
GJ
D000818:Animals; D001402:B-Lymphocytes / Q000166:cytology* / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D007075:Immunoglobulin M / Q000276:immunology / Q000378:metabolism; D007275:Injections, Intravenous; D051379:Mice; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism*; D013205:Staphylococcal Protein A / Q000008:administration & dosage / Q000494:pharmacology*; D018089:Superantigens / Q000276:immunology; D013997:Time Factors
D007075:Immunoglobulin M; D011947:Receptors, Antigen, B-Cell; D013205:Staphylococcal Protein A; D018089:Superantigens